JP2014503191A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503191A5
JP2014503191A5 JP2013537894A JP2013537894A JP2014503191A5 JP 2014503191 A5 JP2014503191 A5 JP 2014503191A5 JP 2013537894 A JP2013537894 A JP 2013537894A JP 2013537894 A JP2013537894 A JP 2013537894A JP 2014503191 A5 JP2014503191 A5 JP 2014503191A5
Authority
JP
Japan
Prior art keywords
synuclein
disease
pharmaceutical composition
ice
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537894A
Other languages
English (en)
Japanese (ja)
Other versions
JP6006908B2 (ja
JP2014503191A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059463 external-priority patent/WO2012061785A2/en
Publication of JP2014503191A publication Critical patent/JP2014503191A/ja
Publication of JP2014503191A5 publication Critical patent/JP2014503191A5/ja
Application granted granted Critical
Publication of JP6006908B2 publication Critical patent/JP6006908B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537894A 2010-11-05 2011-11-04 Ｉｃｅ阻害化合物およびその使用 Expired - Fee Related JP6006908B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41085610P 2010-11-05 2010-11-05
US41085210P 2010-11-05 2010-11-05
US61/410,852 2010-11-05
US61/410,856 2010-11-05
PCT/US2011/059463 WO2012061785A2 (en) 2010-11-05 2011-11-04 Ice inhibiting compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2014503191A JP2014503191A (ja) 2014-02-13
JP2014503191A5 true JP2014503191A5 (enExample) 2014-12-18
JP6006908B2 JP6006908B2 (ja) 2016-10-12

Family

ID=46024857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537894A Expired - Fee Related JP6006908B2 (ja) 2010-11-05 2011-11-04 Ｉｃｅ阻害化合物およびその使用
JP2013537895A Expired - Fee Related JP5980790B2 (ja) 2010-11-05 2011-11-04 バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013537895A Expired - Fee Related JP5980790B2 (ja) 2010-11-05 2011-11-04 バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン

Country Status (4)

Country Link
US (3) US9116157B2 (enExample)
EP (2) EP2635906A4 (enExample)
JP (2) JP6006908B2 (enExample)
WO (2) WO2012061785A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用
KR20170096998A (ko) 2014-11-05 2017-08-25 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 aadc 폴리뉴클레오티드
ES2950100T3 (es) 2016-12-23 2023-10-05 Casp Aid Inc Inhibición de la caspasa-1 y usos de esta para la prevención y el tratamiento de afecciones neurológicas
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
WO2019161302A1 (en) * 2018-02-16 2019-08-22 University Of Southern California Biomarkers for parkinson's disease
JP2021523914A (ja) 2018-05-15 2021-09-09 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． パーキンソン病を治療するための組成物および方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1991015577A1 (en) 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
CA2071674C (en) 1991-06-21 2003-08-19 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
DK0600880T3 (da) 1991-08-30 2004-04-13 Vertex Pharma Interleukin 1-beta-protease og interleukin 1-beta-proteasehæmmere
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
AU1339092A (en) 1991-12-13 1993-07-19 Corvas International, Inc. Reagents for automated synthesis of peptide analogs
WO1993014777A1 (en) 1992-01-31 1993-08-05 Merck & Co., Inc. PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
EP0627926B1 (en) 1992-02-21 1998-08-05 Merck & Co., Inc. (a New Jersey corp.) PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME
FR2698984B1 (fr) 1992-12-04 1995-01-06 Commissariat Energie Atomique Procédé et dispositif d'acquisition d'une image à trois dimensions d'un petit objet par palpage lumineux et moyen d'étalonnage pour la mise en Óoeuvre d'une telle acquisition.
DE69532113T2 (de) 1994-03-31 2004-07-29 Vertex Pharmaceuticals Inc., Cambridge Pyrimidin-derivate als interleukin inhibitoren
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
CA2215211A1 (en) 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
WO1998010778A1 (en) 1996-09-12 1998-03-19 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
AU738341B2 (en) 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
CA2268086A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company Sulfonamide interleukin-1.beta. converting enzyme inhibitors
DE69735230D1 (de) 1996-10-11 2006-04-20 Warner Lambert Company Llc Mor Sulfonamid-substituierte asparaginsäuren als inhibitoren von interleukin-1beta-konvertierenden enzymen
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
JP2002509153A (ja) 1998-01-20 2002-03-26 ワーナー−ランバート・カンパニー インターロイキン−１β変換酵素（ＩＣＥ）のインビボ阻害剤としてのＮ−［２−（５−ベンジルオキシカルボニル−アミノ−６−オキソ−２−（４−フルオロフェニル）−１，６−ジヒドロ−１−ピリミジニル）アセトキシル］−Ｌ−アスパラギン酸アルデヒド
WO1999047154A1 (en) 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
BRPI9909660B8 (pt) 1998-03-19 2021-05-25 Vertex Pharma compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos
CA2327507A1 (en) 1998-05-05 1999-11-11 Warner-Lambert Company Succinamide inhibitors of interleukin-1.beta. converting enzyme
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US6391575B1 (en) * 1999-03-05 2002-05-21 Idun Pharmaceuticals, Inc. Methods for detecting membrane derived caspase activity and modulators thereof
WO2000055127A1 (en) 1999-03-16 2000-09-21 Merck Frosst Canada & Co. Gamma-ketoacid dipeptides as inhibitors of caspase-3
EP1165490B1 (en) 1999-03-16 2006-08-16 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
AU4213500A (en) 1999-04-09 2000-11-14 Cytovia, Inc. Caspase inhibitors and the use thereof
JP4749640B2 (ja) 1999-07-19 2011-08-17 メルク フロスト カナダ リミテツド ピラジノン、このような化合物を含む組成物
DK1163208T3 (da) 1999-08-06 2004-08-16 Vertex Pharma Caspaseinhibitorer og anvendelser deraf
BR0013666A (pt) 1999-08-27 2002-05-14 Cytovia Inc "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
NZ521639A (en) 2000-03-29 2004-05-28 Vertex Pharma Carbamate caspase inhibitors and uses thereof
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
CA2380935A1 (en) 2000-05-23 2001-11-29 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU2001275279B2 (en) 2000-06-07 2007-01-04 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CA2315468A1 (en) 2000-08-10 2002-02-10 Thermax International Corp. Multi grouting system
PE20020500A1 (es) 2000-09-13 2002-06-25 Vertex Pharma Derivados de piperidina, tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas
BR0115546A (pt) 2000-11-21 2003-09-16 Vertex Pharma Inibidores de imidazol e de benzimidazol caspase e usos dos mesmos
MXPA03009647A (es) 2001-04-19 2004-01-29 Vertex Pharma Heterociclildicarbamidas como inhibidores de caspasa.
AU2002305552A1 (en) 2001-05-10 2002-11-18 Abbott Gmbh And Co.Kg Arylsulfonamide ethers, and methods of use thereof
JP4428926B2 (ja) 2001-05-23 2010-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの使用
EP1436248A2 (en) 2001-10-09 2004-07-14 Vertex Pharmaceuticals Incorporated Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
EP1480999A2 (en) 2002-02-08 2004-12-01 Idun Pharmaceuticals (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
WO2003068242A1 (en) 2002-02-11 2003-08-21 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
EP1494700A2 (en) 2002-04-05 2005-01-12 Cytovia, Inc. Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US7138395B2 (en) 2002-06-10 2006-11-21 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7041696B2 (en) 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
PL374598A1 (en) 2002-06-28 2005-10-31 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CN100366612C (zh) 2002-12-20 2008-02-06 沃泰克斯药物股份有限公司 4-氧代-3-(1-氧代-1h-异喹啉-2-基乙酰氨基)-戊酸酯和酰胺衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ES2640669T3 (es) * 2003-05-19 2017-11-03 Prothena Biosciences Limited Fragmentos truncados de alfa-sinucleína en enfermedad con cuerpos de lewy
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
WO2005117846A2 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
US20050202508A1 (en) 2003-11-12 2005-09-15 Pasinetti Guilio M. Biomarker for Parkinson's disease
CN101198598A (zh) 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法
NZ588431A (en) 2004-09-17 2012-02-24 Whitehead Biomedical Inst Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
WO2006086517A2 (en) 2005-02-08 2006-08-17 The Scripps Research Institute Inhibitors of transthyretin amyloid fibril formation
US20070092889A1 (en) 2005-06-02 2007-04-26 Perlegen Sciences, Inc. Parkinson's disease-related disease compositions and methods
EP1976839A4 (en) 2006-01-26 2011-06-15 Foldrx Pharmaceuticals Inc COMPOUNDS AND METHOD FOR MODULATING A PROTEIN TRANSPORT
WO2007129221A2 (en) 2006-02-17 2007-11-15 Waratah Parmaceuticals Inc Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
EP2074223A4 (en) 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS
US8450481B2 (en) 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
WO2010003092A1 (en) * 2008-07-03 2010-01-07 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US20120276019A1 (en) * 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
WO2010054127A1 (en) 2008-11-05 2010-05-14 Elan Pharmaceuticals, Inc. Methods and agents for stabilizing non-pathological amyloidogenic polypeptides
CA2746778C (en) * 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
JP6006908B2 (ja) * 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用
WO2012061788A2 (en) * 2010-11-05 2012-05-10 Brandeis University Tetrameric alpha-synuclein as biomarkers

Similar Documents

Publication Publication Date Title
JP2014503191A5 (enExample)
US12203943B2 (en) Biomarkers of fast progression of chronic kidney disease
Liu et al. VHH phage-based competitive real-time immuno-polymerase chain reaction for ultrasensitive detection of ochratoxin A in cereal
US9134326B2 (en) Biomarkers for liver fibrosis
US10942188B2 (en) Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of COPD
JP2007535930A5 (enExample)
BRPI0821682A2 (pt) Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
BR112012030788B8 (pt) Anticorpo monoclonal, linhagem celular de hibridoma, e métodos para identificar a presença e para determinação quantitativa de uma enzima aad-12
JP2012515226A5 (enExample)
JP2015533788A5 (enExample)
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
EP3526605B1 (en) Method for the detection of apolipoprotein e4
WO2008008463A3 (en) METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPβ
CN105102985A (zh) 用于指导血压下降疗法的肾上腺髓质素
JP2010522875A5 (enExample)
US20230408521A1 (en) Gdf-15 as a diagnostic marker for melanoma
Matsui et al. Development of a monoclonal antibody-based ELISA system for glyceraldehyde-derived advanced glycation end products
WO2005109000A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
CA3199237A1 (en) Methods for identifying and treating antibody-mediated acquired primary or recurrent idiopathic nephrotic syndrome
JP2014518624A5 (enExample)
WO2015160805A1 (en) Circulating kim-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
JP2014224759A5 (enExample)
JP2009507471A5 (enExample)
WO2012165926A3 (ko) 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
BRPI0606307A2 (pt) formas de fator xlla e métodos para determinar as referidas formas